logo
Plus   Neg
Share
Email

Roche Reports Results From Evrysdi Study In Infants With Type 1 Spinal Muscular Atrophy

Roche reported results from Evrysdi study in infants with type 1 spinal muscular atrophy. The data showed that treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support for at least 5 seconds, which is not normally seen in the natural course of the disease. The treatment with Evrysdi increased the levels of survival of motor neuron protein by a median 1.9-fold from baseline in the high-dose cohort at 12 months.

The FDA approved Evrysdi in 2020 for the treatment of spinal muscular atrophy in adults and children 2 months of age and older. Evrysdi was granted PRIME designation by the European Medicines Agency in 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney World, the Orlando, Florida-based entertainment complex, is easing the health safety guidelines that were rolled out to prevent the spread of the ongoing COVID-19 pandemic. The complex is ending temperature checks in a phased manner following the advice of the Centers for Disease Control and Prevention (CDC) and local health officials. Frito-Lay North America, the convenient foods division of food and beverages giant PepsiCo, Inc., is recalling select Ruffles All Dressed Potato Chips citing the possible presence of undeclared milk ingredients, a known allergen, the U.S. Food and Drug Administration said. According to the agency, the recalled products may have distributed regionally to Walmart's Sam's Club Warehouses. Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The companies initiated...
Follow RTT